

REMARKS

The applicant requests that the examiner update to attorney docket number in this application as indicated above. The attorney docket number currently used by the examiner is that of a prior law firm no longer involved in current prosecution.

A. Amendments to the claims

The amendments made herein merely clarify that which applicant regards as the invention and/or improve readability of the claims. The amendments include no new matter and do not change the scope of the claims.

Specifically, claims 1, 18-21 and 24-26 have been amended to recite "at least one" tetraalkylammonium tetrathiomolybdate instead of "at least a first" tetraalkylammonium tetrathiomolybdate. Support for this amendment can be found in the specification, for example, in paragraphs [0239] and [0015] of U.S. 2004/0259945 A1 (i.e., the application as published; all further references to paragraph numbers will refer to this patent application publication). Claims 2-5, 12 and 14 have been amended to improve readability. Claims 6-9 have been made dependent from 5 in addition to being dependent upon claim 1. Support for this amendment can be found in the specification, for example, at paragraphs [0027] and [0028]. Claims 9 and 18 have been amended to recite a therapeutic agent that is different from the tetraalkylammonium tetrathiomolybdate compound. The amendment does not suggest that tetraalkylammonium tetrathiomolybdate is not in itself therapeutic; the therapeutic property of tetraalkylammonium tetrathiomolybdate is inherently recited in the independent claims. Claims 9, 11, 13, 16, 18, 21-26 have been amended to remove superfluous language. Claims 11 and 13 have been amended to recite that the therapeutic agent is an anti-angiogenic agent or anti-cancer agent, respectively. Support for this amendment can be found in the specification, for example, at paragraphs [0034] and [0036]. Claim 15 has been amended to clarify that the tetraalkylammonium tetrathiomolybdate compounds of the invention are more stable compared to ammonium tetrathiomolybdate. Support for this amendment can be found in the specification, for example, at paragraphs [0172], [0173], [0423] and [0424]. Claims 12, 14, 16 and 26 have been amended to correct grammatical errors.

B. The Rejection under 35 USC §112, second paragraph

The examiner rejected claims 1 through 14 under 35 USC §112, second paragraph, for assertedly being indefinite. Specifically, the examiner alleged that recitation of the phrase "at least a first tetraalkylammonium tetrathiomolybdate" fails to set forth secondary or other components intended to be added to the composition.

While the applicant disagrees with the examiner's position, the amendment to claim 1 to specify at least one tetraalkylammonium tetrathiomolybdate obviates the rejection. As originally-filed and as amended in order to expedite prosecution, claim 1 does not imply that other components are necessarily to be added to the composition, even though addition of other components is encompassed by the claim.

CONCLUSION

In view of the amendments and remarks made herein, the applicant believes that all claims are now in condition for allowance and request notification of the same.

Dated: October 17, 2006

Respectfully submitted,

By 

Joseph A. Williams, Jr.

Registration No.: 38,659

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant